EpiVario Inc.
About EpiVario Inc.
EpiVario, Inc. is a biotechnology company founded in 2017 that develops novel epigenetic therapeutics targeting the metabolic control of gene regulation for neuropsychiatric disorders. Its pipeline focuses on small-molecule inhibitors of acetyl-CoA synthetase 2 (ACSS2) to address memory-related conditions including substance use disorders, opioid and alcohol addictions, and PTSD. The company is headquartered at 601 Walnut Street in Philadelphia, PA, and has received sponsored research funding and licensed IP from the University of Pennsylvania. Revenue is estimated in the $1M-$10M range.
- 🔗 EpiVario, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 EpiVario - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 EpiVario, Inc. Valuation, Share Price & Funding | Caplight
- 🔗 EpiVario - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 Epivario Inc
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Developing small-molecule ACSS2 inhibitors for PTSD and substance-use disorders
- Received multiple NIH/HHS grants totaling several hundred thousand dollars
- Licensed IP and sponsored research ties to University of Pennsylvania
- Total funding reported at $1.3M across grants and placements
- Targeting memory-related addictions affecting over 14 million U.S. adults
Ask StreetZero about EpiVario Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account